A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00034619 |
|
Recruitment Status :
Completed
First Posted : May 2, 2002
Last Update Posted : July 19, 2006
|
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer | Drug: ALIMTA Drug: Oxaliplatin | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Primary Purpose: | Treatment |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Colorectal Cancer
U.S. FDA Resources
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of primary cancer of the colon or rectum
- Must have measurable disease
- Must be able to comply with study procedure
Exclusion Criteria:
- Prior chemotherapy for advanced disease
- Pregnancy or lactation
- Candidates for surgical resection of one or more metastatic foci
- Second primary cancer
- Inability to take folic acid or vitamin B12
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00034619
Locations
| United States, Alabama | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Huntsville, Alabama, United States | |
| United States, Massachusetts | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Pittsfield, Massachusetts, United States | |
| United States, Michigan | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Kalamazoo, Michigan, United States | |
| United States, New York | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Latham, New York, United States | |
| United States, North Carolina | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Asheville, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Goldsboro, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Hendersonville, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Winston-Salem, North Carolina, United States | |
| United States, Ohio | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Columbus, Ohio, United States | |
| United States, Oregon | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Bend, Oregon, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Philadelphia, Pennsylvania, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Pittsburgh, Pennsylvania, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Reading, Pennsylvania, United States | |
| United States, South Carolina | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Charleston, South Carolina, United States | |
| United States, Utah | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Ivins, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Ogden, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Provo, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| St. George, Utah, United States | |
| United States, Washington | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Bellevue, Washington, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Seattle, Washington, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Spokane, Washington, United States | |
Sponsors and Collaborators
Eli Lilly and Company
| ClinicalTrials.gov Identifier: | NCT00034619 History of Changes |
| Other Study ID Numbers: |
5142 H3E-MC-JMEP |
| First Posted: | May 2, 2002 Key Record Dates |
| Last Update Posted: | July 19, 2006 |
| Last Verified: | July 2006 |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Oxaliplatin Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |